.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Emerging Treatment Patterns for Hepatocellular Carcinoma

EP. 1: Treatment Strategies for Early-Stage HCC

November 28th 2018

EP. 2: Global Perspective on Locoregional Therapies in HCC

November 28th 2018

EP. 3: Combining TACE With Systemic Therapy in Advanced HCC

November 28th 2018

EP. 4: Locoregional Therapy in HCC: Additional Considerations

November 28th 2018

EP. 5: Radiotherapy Use in HCC

November 28th 2018

EP. 6: Prognostic and Predictive Markers in HCC

November 28th 2018

EP. 7: Sorafenib Initiation After TACE in HCC

November 28th 2018

EP. 8: Lenvatinib As Up-front Therapy for Unresectable HCC

November 28th 2018

EP. 9: Regorafenib Following First-Line Systemic Therapy in HCC

November 28th 2018

EP. 10: Sequencing With Cabozantinib in Advanced HCC

November 28th 2018

EP. 11: Ramucirumab After Progression in Advanced HCC

November 28th 2018

EP. 12: Considerations for Using Nivolumab in Advanced HCC

November 28th 2018

EP. 13: Opportunities for Checkpoint Inhibitors in Advanced HCC

November 28th 2018

EP. 14: Emerging Novel Combinations in Advanced HCC

November 28th 2018

EP. 15: The Management of HCC: Moving Forward

November 28th 2018